celltrials.org

What It Is

CellTrials.org / Cell Trials Data does not appear, based on the extracted text, to be a typical online course platform. Instead, it is a provider of specialized datasets for cell therapy, gene therapy, and related life sciences niches. Its core products are searchable and sortable Excel databases, such as exosome clinical trials, in vivo gene therapy trials, MSC clinical trials, cell and gene therapy CMO/CDMO facilities, cord blood banks, and more.

Core Content and Format

Its “course category” would be more accurately described as biomedical data research and industry intelligence. The exosome database covers 444 trials from 2011–2025 and 24 source publications related to those trials; the in vivo gene therapy database covers 879 trials from 2011–2021; and the MSC database states that it draws from more than 15 international registries, emphasizing that a substantial share is not listed on ClinicalTrials.gov. In terms of delivery format, the pages do not show information about live classes, recorded lessons, or 1-on-1 instruction. The main deliverables are Excel files and sample downloads. No certification or completion certificate information was found either.

Pricing and Service

Pricing is based on one-time dataset purchases: exosome clinical trials cost USD 1,550; gene therapy costs USD 900; six months of MSC data costs USD 750; 4.5 years of MSC data costs USD 1,250; CMO/CDMO facilities cost USD 700; cord blood banks cost USD 500; and psychiatric psychedelic drug products cost USD 1,000. COVID-19 cell therapy trial data is free, academic datasets are also marked as free, and custom dataset pricing is negotiable. Payment methods are not disclosed in the text.

Pros and Cons

The main advantage is that the topics are narrow but deep, with clearly structured fields such as registration date, country, phase, status, route of administration, dose, indication, and sponsor, making the data suitable for direct filtering and statistical analysis. Some products emphasize manual screening and integration across multiple registries, which is valuable for studying global trials beyond ClinicalTrials.gov. The downside is the high price threshold, along with the lack of teaching explanations, learning paths, certificates, or interactive service descriptions. As a result, if evaluated as an “education/course” product, the learning experience is limited.

Who It’s For and Access from China

It is suitable for biomedical companies, investment research/BD teams, clinical trial analysts, cell and gene therapy research teams, and academic researchers. It is not suitable for individual learners looking for a structured introductory course on cell therapy. The text does not state whether access from mainland China is reliable, whether network stability is good, or whether payment is available, so these remain unknown. Alternatives include ClinicalTrials.gov, WHO ICTRP, national registries, and in-house literature search workflows, though these typically require more cleaning and screening work.